GlaxoSmithKline Plc, which has a gene therapy on the market, is broadening its portfolio of advanced therapy medicinal products to include potential new treatments derived from induced pluripotent stem cells (iPSC). iPSCs are a type of pluripotent stem cell that can be generated directly from adult cells.
